Publication:
Gamma knife radiosurgery for pituitary spindle cell oncocytomas

dc.contributor.coauthorOzdemir, Inan Erdem
dc.contributor.coauthorSengoz, Meric
dc.contributor.kuauthorAkyoldaş, Göktuğ
dc.contributor.kuauthorHergünsel, Ömer Batu
dc.contributor.kuauthorPeker, Selçuk
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileDoctor
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteN/A
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.unitKoç University Hospital
dc.contributor.yokid203677
dc.contributor.yokidN/A
dc.contributor.yokid11480
dc.date.accessioned2024-11-09T23:38:55Z
dc.date.issued2019
dc.description.abstractObjectives: Spindle cell oncocytomas (SCOs) are benign lesions of the posterior portion of the pituitary gland that typically come to neurosurgical attention due to compression of the sellar or parasellar structures, and headaches. Initial treatment options for SCOs include surgical resection, particularly via the transsphenoidal approach. However, given that initial resection tends to be insufficient and subsequent revision surgery carries high complication risk, adjuvant treatment modalities may appear to offer promising solutions for controlling tumor progression. This report focuses on a potential new therapeutic option for SCOs, gamma knife radiosurgery (GKRS). Patients and methods: The authors identified all patients at one center who had a pituitary lesion treated with GKRS between 2005 and 2016. Five patients with histopathologically confirmed SCO who underwent GKRS were retrospectively identified and included in the present study Results: The mean patient age was 52 years (range, 41-61 years). The most common presenting symptom was visual disturbance. All five patients had a history of transsphenoidal surgical resection prior to GKRS therapy. The mean tumor volume was 2.25 cm(3) (range 0.7-5.38 cm(3)). The median tumor margin dose was 12 Gy (range, 12-14 Gy), and the median maximal dose was 24 Gy (range, 24-35 Gy). The median isodose was 50 (range, 40-50). No tumor volume progression was observed during radiological follow-up after GKRS (mean, 52 months; range, 36-84 months). At last follow-up, no neurological, endocrinological, or visual complications had been observed. Conclusion: Given their highly vascular and adherent nature, SCOs can be challenging tumors to treat, in particular when they recur. In our five cases, GKRS provided excellent tumor volume control for approximately 4.3 years on average. These results suggest that GKRS is a safe and effective treatment modality for histopatholo-gically confirmed residual SCO.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessNO
dc.description.volume187
dc.identifier.doi10.1016/j.clineuro.2019.105560
dc.identifier.eissn1872-6968
dc.identifier.issn0303-8467
dc.identifier.scopus2-s2.0-85073514535
dc.identifier.urihttp://dx.doi.org/10.1016/j.clineuro.2019.105560
dc.identifier.urihttps://hdl.handle.net/20.500.14288/13028
dc.identifier.wos500365200009
dc.keywordsSpindle cell
dc.keywordsOncocytomas
dc.keywordsSellar
dc.keywordsMass
dc.keywordsPituitary
dc.keywordsTranssphenoidal
dc.keywordsRevision
dc.keywordsStereotactic radiosurgery
dc.keywordsGamma knife
dc.keywordsOncology
dc.languageEnglish
dc.publisherElsevier
dc.sourceClinical Neurology and Neurosurgery
dc.subjectClinical neurology
dc.subjectSurgery
dc.titleGamma knife radiosurgery for pituitary spindle cell oncocytomas
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0003-4234-6520
local.contributor.authorid0000-0003-3143-0575
local.contributor.authorid0000-0003-3057-3355
local.contributor.kuauthorAkyoldaş, Göktuğ
local.contributor.kuauthorHergünsel, Ömer Batu
local.contributor.kuauthorPeker, Selçuk

Files